Literature DB >> 17596592

Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery.

V Casati1, A D'Angelo, L Barbato, D Turolla, F Villa, M A Grasso, A Porta, F Guerra.   

Abstract

Previous studies have demonstrated that preoperative haemoglobin concentration and female gender are related to an increased need for perioperative allogeneic transfusions in cardiac surgery. Hence, urgent cardiac surgery presents a dilemma for female patients who are Jehovah's Witnesses, because of their refusal of allogeneic transfusion. This report describes the management of four high-risk anaemic female patients undergoing urgent complex cardiac surgery. In these Jehovah's Witness patients, strict application of a comprehensive blood-sparing protocol permitted safe avoidance of allogeneic transfusions. The protocol involved intraoperative acute normovolaemic haemodilution, intraoperative administration of tranexamic acid, intra- and postoperative use of a cell-saver system, postoperative administration of erythropoietin, iron and folic acid, and a careful surgical technique to avoid perioperative bleeding.

Entities:  

Mesh:

Year:  2007        PMID: 17596592     DOI: 10.1093/bja/aem170

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

1.  Bloodless third complex heart operation in a Jehovah's Witness patient with extremely low preoperative haemoglobin level.

Authors:  Miralem Pasic; Giuseppe D'Ancona; Axel Unbehaun; Roland Hetzer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-20

2.  High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.

Authors:  Andrei M Beliaev
Journal:  Blood Transfus       Date:  2013-03-19       Impact factor: 3.443

3.  Risk-adjusted clinical outcomes in patients enrolled in a bloodless program.

Authors:  Steven M Frank; Elizabeth C Wick; Amy E Dezern; Paul M Ness; Jack O Wasey; Andrew C Pippa; Elizabeth Dackiw; Linda M S Resar
Journal:  Transfusion       Date:  2014-06-18       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.